FDA’s June 2024 list of off-patent, off-exclusivity drugs sees rise in cancer, HIV treatments
This week PharmaCompass brings to you key highlights of the US Food and Drug Administration’s
Chinese industrial activity revival at 98.6 percent, officials assure of API supplies
While the world feels the heat of the Covid-19 pandemic with the global pharmaceutical supply chain
COVID-19: India restricts drug exports amid rising prices of essential bulk drugs; FDA announces first drug shortage
Now that it has been
established that the novel coronavirus is going to globally impact the drug
s
FDA’s 2016 Approvals of New Drugs, Formulations, Strengths & More
After 2 years of sky-high approval numbers, the US Food and Drug Administration’s (FDA) Center